SCHEMBL3012787

SCHEMBL3012787

COc1ccc(-c2csc(N3CCN(S(=O)(=O)c4ccc(Br)cc4Cl)CC3)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.56
RAB9A P51151 3/20 0.53
NPC1 O15118 1/20 0.53
MAPT P10636 5/20 0.52
USP2 O75604 2/20 0.52
RECQL P46063 1/20 0.52
HSD17B10 Q99714 1/20 0.52
SMN1; SMN2 Q16637 6/20 0.50
ALDH1A1 P00352 4/20 0.50
LMNA P02545 4/20 0.50
MAPK1 P28482 4/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
TP53 P04637 1/20 0.47
ALOX15 P16050 1/20 0.47
HTT P42858 1/20 0.47
FAAH O00519 1/20 0.46
EPHX2 P34913 1/20 0.46
MMP1 P03956 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3004360 0.93 MAPT (0.54) POLBRAB9ANPC1MAPTUSP2
SCHEMBL3003209 0.90 POLB (0.58) POLBRAB9ANPC1MAPTUSP2
SCHEMBL3021654 0.90 LMNA (0.50) POLBRAB9ANPC1MAPTUSP2
SCHEMBL3016571 0.90 MAPT (0.66) POLBMAPTUSP2RECQLHSD17B10
SCHEMBL3003134 0.89 SMN1; SMN2 (0.53) POLBRAB9ANPC1MAPTUSP2
SCHEMBL3009087 0.89 SMN1; SMN2 (0.54) RAB9ANPC1MAPTHSD17B10SMN1; SMN2
SCHEMBL3013634 0.89 SMN1; SMN2 (0.56) POLBRAB9ANPC1MAPTUSP2
SCHEMBL3011654 0.89 POLB (0.56) POLBRAB9ANPC1MAPTUSP2
SCHEMBL3020358 0.89 MAPT (0.61) POLBRAB9ANPC1MAPTUSP2
SCHEMBL3647554 0.88 MAPT (0.64) POLBMAPTUSP2RECQLHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA POLB 4649/4885RAB9A 2943/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.